IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 311 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104,237 | +3.5% | 2,298 | -6.4% | 0.00% | 0.0% |
| Q2 2023 | $100,729 | +37.8% | 2,455 | +20.0% | 0.00% | – |
| Q1 2023 | $73,124 | -8.1% | 2,046 | -2.8% | 0.00% | -100.0% |
| Q4 2022 | $79,544 | -16.3% | 2,106 | -2.2% | 0.00% | 0.0% |
| Q3 2022 | $95,000 | +20.3% | 2,153 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $79,000 | -16.8% | 2,147 | -16.4% | 0.00% | 0.0% |
| Q1 2022 | $95,000 | +21.8% | 2,568 | -0.1% | 0.00% | – |
| Q4 2021 | $78,000 | -12.4% | 2,571 | -3.3% | 0.00% | – |
| Q3 2021 | $89,000 | -21.9% | 2,660 | -7.3% | 0.00% | – |
| Q2 2021 | $114,000 | +14.0% | 2,868 | +28.3% | 0.00% | – |
| Q1 2021 | $100,000 | -28.6% | 2,235 | -9.7% | 0.00% | -100.0% |
| Q4 2020 | $140,000 | +15.7% | 2,474 | -2.8% | 0.00% | 0.0% |
| Q3 2020 | $121,000 | -21.9% | 2,546 | -3.0% | 0.00% | 0.0% |
| Q2 2020 | $155,000 | +12.3% | 2,625 | -9.8% | 0.00% | 0.0% |
| Q1 2020 | $138,000 | -23.8% | 2,910 | -3.1% | 0.00% | 0.0% |
| Q4 2019 | $181,000 | -3.2% | 3,002 | -4.1% | 0.00% | 0.0% |
| Q3 2019 | $187,000 | -7.0% | 3,129 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $201,000 | -15.2% | 3,129 | +7.3% | 0.00% | 0.0% |
| Q1 2019 | $237,000 | +45.4% | 2,916 | -3.4% | 0.00% | 0.0% |
| Q4 2018 | $163,000 | +4.5% | 3,019 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $156,000 | +23.8% | 3,019 | 0.0% | 0.00% | – |
| Q2 2018 | $126,000 | +1.6% | 3,019 | +7.2% | 0.00% | – |
| Q1 2018 | $124,000 | -15.6% | 2,817 | -3.7% | 0.00% | – |
| Q4 2017 | $147,000 | -3.3% | 2,925 | -2.3% | 0.00% | -100.0% |
| Q2 2017 | $152,000 | +38.2% | 2,994 | +9.2% | 0.00% | – |
| Q1 2017 | $110,000 | -19.1% | 2,741 | -3.7% | 0.00% | -100.0% |
| Q4 2016 | $136,000 | -99.9% | 2,845 | 0.0% | 0.00% | – |
| Q3 2016 | $104,241,000 | +50.8% | 2,845 | -4.1% | 0.00% | – |
| Q2 2016 | $69,125,000 | -82.5% | 2,968 | -69.5% | 0.00% | -100.0% |
| Q1 2016 | $395,000,000 | -42.0% | 9,718 | -11.7% | 0.00% | -33.3% |
| Q4 2015 | $681,000,000 | – | 11,001 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |